medigraphic.com
ISSN 2007-6509 (Print)
Órgano oficial de la Asociación Mexicana de Medicina Transfusional A.C.

2024, Number 1

<< Back Next >>

Rev Mex Med Transfus 2024; 16 (1)

Current status of altruistic blood donation (AD) at the Hospital Infantil Teletón de Oncología

Méndez MA, Olivares ZVD, Ramos QM, Zamora LD, Núñez TP, Martínez TD, Aguilar ED, Escamilla AG, Vega VL

Language: Spanish
References: 14
Page: 23-29
PDF size: 204.84 Kb.


ABSTRACT

Introduction: in Mexico, the donation for family replacement predominates. Blood banks face difficulties in supplying blood and in guaranteeing the quality and safety of blood components. The experience of the altruistic donation (DA) model implemented at the Teleton Children's Hospital of Oncology is described. Material and methods: retrospective, cross-sectional, descriptive and observational study. Blood donors who attended in the Teleton Children's Hospital of Oncology from December 7, 2013 to June 30, 2023 were included; blood donors who abandoned the process were excluded. The frequency of regular donors and the frequency of seropositive donors were quantified. The use profile of the obtained products is described. Demographic data was obtained from the e-Delphyn® electronic system, continues and categorical variables are described with measures of central tendency and proportions, respectively. Results: of 17,689 predonors, 11,968 donors were suitable. 179 external collections were made. The frequency of positive serological makers was 0.08%. A total of 20,454 transfusions were performed: 11,258 (55%) platelet apheresis, 5,607 (27.5%) acked erythrocytes, 1,749 (8.4%) fresh plasma, 1,835 (8.9%) cryoprecipitates, 2 (0.009%) reconstituted whole blood and 0.014% (3) lymphocyte units. Conclusions: transfusions are a fundamental support treatment in pediatric cancer patients.


REFERENCES

  1. Organización Mundial de la Salud. El cáncer infantil. Geneva: OMS; 2021. Disponible en: http://www.who.int/es/news-room/fact-sheets/detail/cancer-in-children

  2. Muñoz Aguirre P, Zapata Torres M, Espinosa Tamez P et al. Childhood acute lymphoblastic leukemia in Mexico: mortality trend analysis, 1998-2018. Salud Publica Mex. 2022; 64: 126-134.

  3. Secretaría de Salud. Cáncer infantil en México. Disponible en: https://www.gob.mx/salud/articulos/cancer-infantil-en-mexico

  4. Rivera Luna R, Velasco Hidalgo L, Zapata Torres M, Cárdenas Cardos R, Aguilar Ortiz MR. Current Outlook of childhood cancer epidemiology in a middle income country under a public health insurance program. Pediatric Hematol Oncol. 2017; 34 (1): 43-50.

  5. World Health Organization & International Federation of Red Cross and Red Crescent Societies. Towards 100% voluntary blood donation: a global framework for action. World Health Organization. 2010. Available in: https://iris.who.int/handle/10665/44359

  6. PAHO. Suministro de sangre para transfusiones en los países de Latinoamérica y del Caribe 2014-2015. Washington, D. C.: OPS; 2017.

  7. PAHO. Suministro de sangre para transfusiones en los países de América Latina y el Caribe 2016-2017. Washington, D.C.: OPS; 2020. Disponible en: http://iris.paho.org/handle/10665.2/52150

  8. Rojo Medina J. Panorama de la donación voluntaria en México y propuesta de cambio de esquema de la donación de sangre. Rev Mex Med Tran. 2018; 11 (1): S35-S60.

  9. American Association of Blood Banks (AABB). Standards for Blood Banks and Transfusion Services. 27th ed. Bethesda, MD: AABB; 2014.

  10. Ratko TA, Cummings JP, Oberman HA et al; University Health System Consortium. Evidence-based recommendations for the use of WBC-reduced cellular blood components. Transfusion. 2001; 41 (10): 1310-1399.

  11. Sharma RR, Marwaha N. Leukoreduced blood components: advantages and strategies for its implementation in developing countries. Asian J Transfus Sci. 2010; 4 (1): 3-8.

  12. Bowden RA, Slichter SJ, Sayers M et al. A comparison of filtered leukocytereduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood. 1995; 86 (9): 3598-3603.

  13. Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med. 1997; 337 (26): 1861-1869.

  14. McCullough JJ. Clinical uses of blood components. In: McCullough JJ. Transfusion medicine. 3rd ed. Chichester, West Sussex, UK: Wiley-Blackwell; 2011.




2020     |     www.medigraphic.com